Ono Pharmaceuticals joins J-MUG with implementation of Rave®

Ono Pharmaceuticals has chosen Rave® by Medidata Solutions (#medidata). Ono Pharmaceutical Co., Ltd. will use Rave® as its electronic data capture (EDC) and clinical data management (CDM) solution. Rave® has successfully impressed Ono with its capabilities to improve operational efficiency and enhance workflow throughout the clinical trial process.

Ono specialises in oncology, carpal tunnel syndrome, diabetes and other therapeutic areas, and has selected Medidata's services also because of its strong global presence and dependability. Ono seeks to develop candidate compounds for new drugs and actively conduct trials outside Japan. They deployed the Rave® system across a no. of trials in therapeutic areas and valued the system's advantages.

Ono recently participated in the Japan Medidata User Group (J-MUG), to share experiences, best practices and knowledge. J-MUG is a group of over 40 companies which are currently using Medidata services. Ono also plans to actively participate in J-MUG 2012.

About Ono Pharmaceuticals:

Ono Pharmaceutical Co. Ltd. has always strived to achieve its goal of serving as R&D-oriented global specialty pharmaceuticals, aiming to develop innovative and globally recognized drugs. Ono has been engaged in drug discovery research based on accumulated technologies and know-how in areas where Ono’s strengths can be fully exploited.

To find out more about Medidata's solutions and service offerings, contact Kiyoshi Tsunoda, Marketing Manager, Medidata at ktsunoda@mdsol.com.

Tetsuomi Takano, Senior Director & Head, Asian Project Management, Asian Development, Astellas Pharma, Japan, will be presenting at Pharma Trials World Asia 2012 this March on "Exploiting the favourable environment in East Asia."

Click here to register your attendance at this conference now.